Image
illustration
Venture Capital Acquisitions & Partnerships

XERIS PHARMACEUTICALS enters a collaboration agreement with Merck

Monday 25 October, 2021
Body

The agreement includes an option to license Xeris' suspension-based formulation technology, XeriJect, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations.

Content